This study will evaluate whether the anti-inflammatory effect of colchicine is beneficial in ACS patients

This study will evaluate the effect of colchicine on inflammation, cardiac remodeling, and atherosclerotic risk in STEMI patients through the assessment of the IL-1β, sST2, and lipid profile parameters as well as to examine the drug safety and tolerability in these patients.

Inclusion Criteria:

• male or female
• >18 yrs
• STEMI patients who were successfully treated with PCI.

Exclusion Criteria:

• Pregnant or breast-feeding women or women of childbearing potential.
• Active inflammatory, known malignancy, infectious diseases or current treatment with corticosteroids or anti inflammatory agents.
• Known hypersensitivity to colchicine or current chronic treatment with colchicine.
• Severe renal failure (estimated creatinine clearance <30ml/min) or hepatic failure (Child Pugh score B or C )
• Cardiac arrest, ventricular fibrillation, cardiogenic shock or previous myocardial infarction.
• Patients using the following agents: Strong CYP3A4 inhibitors (ritonavir, clarithromycin, ketoconazole, voriconazole, itraconazole), intermediate CYP3A4 inhibitors (aprepitant, diltiazem, erythromycin, fluconazole, verapamil), P-gp inhibitor (amiodarone, clarithromycin, erythromycin, azithromycin, ranolazine, verapamil, ketoconazole, itraconazole) and grape fruit juice

Electrocardiography parameters assessors and clinical laboratory technicians were masked to the study patient group allocation